SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is currently a focal point due to intense speculation surrounding its reported all-cash revised bid for Warner Bros. Discovery, a move that comes amidst a contentious bidding war and legal challenges from a rival suitor. The community is sharply divided, with bulls anticipating a significant run-up and potential short squeeze ahead of upcoming earnings, while cautious investors highlight potential regulatory hurdles and the stock's recent volatility. This acquisition drama underscores the ongoing strategic battle for content and market share within the streaming industry.

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

Super Micro Computer is highly active after a significant downgrade and "Sell" rating from Goldman Sachs spurred widespread discussion. The community is sharply divided, with many seeing the move as institutional manipulation designed to depress the stock for cheaper accumulation, while others underscore ongoing concerns regarding the company's profit margins and management execution. As a critical infrastructure provider in the booming AI sector, investors are closely watching how the company navigates these challenges.

JPMorgan Chase & Co. is a financial holding company, which engages in the provision of financial and investment banking services. It focuses on investment banking, financial services for consumers and small businesses, commercial banking, financial transaction processing, and asset management. It operates through the following segments: Consumer and Community Banking (CCB), Commercial and Investment Bank (CIB), Asset and Wealth Management (AWM), and Corporate. The CCB segment originates and services mortgage loans. The CIB segment makes markets and services clients across fixed income, foreign exchange, equities, and commodities. The AWM segment provides initial capital investments in products such as mutual funds and capital invested alongside third-party investors. The Corporate segment manages its liquidity, funding, capital, structural interest rate, and foreign exchange risks. The company was founded in 1799 and is headquartered in New York, NY.

JPMorgan Chase & Co.

JPMorgan Chase & Co

JPMorgan is trending following its recent financial report, which included a notable impact from acquiring a new credit card portfolio. The community is actively debating this development, alongside significant concerns about a proposed cap on credit card interest rates that the bank's leadership has publicly stated would necessitate major business adjustments. Despite an initial market reaction, many investors are discussing whether this presents a "buy the dip" opportunity for the financial institution.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TG Therapeutics is trending due to robust revenue estimates for Briumvi through 2026, fueled by strong demand and positive updates from investor presentations. The community is actively discussing the company's significant growth potential and its best-in-class drug profile, alongside ongoing frustration over perceived stock manipulation and the lack of a major price breakout. With competing therapies facing setbacks, many anticipate substantial long-term value appreciation, while some remain skeptical given past stock performance.

Adobe, Inc. is a global technology company, which engages in the provision of digital marketing and media solutions. It operates through the following segments: Digital Media, Digital Experience, and Publishing and Advertising. The Digital Media segment offers products and services that enable individuals, teams, businesses, and enterprises to create, publish, and promote content anywhere and accelerate productivity by transforming view, share, engage with and collaborate on documents and creative content. The Digital Experience segment focuses on integrated platform and set of products, services, and solutions that enable businesses to create, manage, execute, measure, monetize, and optimize customer experiences that span from analytics to commerce. The Publishing and Advertising segment includes legacy products and services that address diverse market opportunities, including eLearning solutions, technical document publishing, web conferencing, document and forms platform, web app development, high-end printing, and Adobe Advertising offerings. The company was founded by Charles M. Geschke and John E. Warnock in December 1982 and is headquartered in San Jose, CA.

Adobe Inc

Adobe is trending amid a flurry of analyst downgrades, citing intensified AI competition and its potential impact on the company's growth and valuation, exacerbated by new competitive offerings like Apple's creative suite. Community sentiment is sharply divided, with many fearing AI will render Adobe's offerings obsolete, while others view the stock as a deeply undervalued 'cash cow' with impeccable financials. This debate is set against a broader market re-evaluation where software stocks are facing pressure to effectively monetize AI.

Ambitions Enterprise Management Co. LLC operates as a travel agency. It provides event planning and management services. The firm also offers transportation, accommodations, meals, and guided tours or activities under convenient packages. The company was founded on October 26, 2023 and is headquartered in Dubai, United Arab Emirates.

Ambitions Enterprise Management Co LLC - Ordinary Shares - Class A

Ambitions Enterprise Management Co LLC

Ambitions Enterprise Management Co. (AHMA) is actively trending due to a significant surge in both price and trading volume. This rapid movement is fueling community discussions about its notably low float, leading to speculation around a potential short squeeze, with many drawing parallels to past parabolic runners despite the absence of clear fundamental news and some concerns about potential share offerings.

Bitmine Immersion Technologies, Inc. is a technology company focused on acquiring, holding, and actively managing ETH as its primary treasury reserve asset. It prioritizes digital ecosystem services, such as consultancy and advisory works. The company was founded on August 16, 1995 and is headquartered in Las Vegas, NV.

BitMine Immersion Technologies Inc

Bitmine Immersion Technologies Inc

BMNR is trending due to an imminent shareholder vote on a significant increase in authorized shares, sparking intense community debate over potential dilution versus enabling aggressive Ethereum acquisition and long-term growth. Many investors are weighing trust in management's vision for ETH tokenization and staking against concerns about the impact on current share value, especially given recent Ethereum price fluctuations.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax is trending with significant community speculation ahead of its presentation at the J.P. Morgan Healthcare Conference, following a recent analyst upgrade and an 8-K filing hinting at new partnerships and strategic de-risking. Investors are closely watching for updates on the company's Matrix-M adjuvant platform for potential beyond infectious diseases, while high short interest fuels discussions of a potential squeeze. Despite this positive momentum, many on the forums remain skeptical about current management's ability to capitalize on these opportunities.

Red Cat Holdings, Inc. provides products, services and solutions to the drone industry. It also engages in the provision of distributed data storage, analytics and services for the drone industry.The firm product include Dronebox, which is a blockchain technology that records, stores and analyzes flight data and information from a drone. It operates through the Enterprise Segment. The Enterprise Segment will focus on developing a hardware enabled software platform of services and solutions to government and commercial enterprises and the military. The company was founded by Jeffrey M. Thompson in February 1984 and is headquartered in San Juan, Puerto Rico.

Red Cat Holdings Inc

Red Cat Holdings (RCAT) is surging after reporting preliminary Q4 revenue results indicating massive year-over-year growth, sparking widespread excitement. The community is buzzing with talk of a potential short squeeze, driven by strong belief in its U.S.-made defense drone technology and anticipation of new details from an upcoming industry conference. This positions RCAT at the forefront of the accelerating demand within the defense and drone sectors.

BriaCell Therapeutics Corp. is a clinical-stage biotechnology company, which engages in the development of novel immunotherapies to transform cancer care. It currently advancing its Bria-IMT™ targeted immunotherapy in combination with an immune check point inhibitor in a pivotal 1 Phase 3 study in metastatic breast cancer. The company was founded by Charles L. Wiseman and Isaac Benjamin Maresky on July 26, 2006 and is headquartered in West Vancouver, Canada.

BriaCell Therapeutics Corp - Ordinary Shares - New

BriaCell Therapeutics Corp

BriaCell Therapeutics (BCTX) is trending due to reports of a sustained complete resolution of lung metastasis in a metastatic breast cancer patient treated with its Bria-OTS therapy, generating significant excitement about a potential breakthrough. However, community sentiment is divided, with many celebrating the "game changer" news while a skeptical portion anticipates another offering or "pump and dump" given the company's past history of frequent capital raises and stock consolidations following positive announcements.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Fossil Group (FOSL) shares were down nearly 39% in premarket trading on Thursday morning after the company said on Thursday that it has further extended the&nbsp;expiration of the exchange offer concerning its 7.00% Senior Notes due 2026.The company also noted that it has extended the consent solicitation and its concurrent rights offering from October 15 to October 22.Separately, the company stated that it is not currently pursuing an initial public offering of its subsidiary in India, following recent media reports about the subsidiary going public.Retail sentiment on Fossil Group jumped to ‘extremely bullish’ from ‘bearish’ territory a day ago, with message volumes at ‘extremely high’ levels, according to data from Stocktwits.On Wednesday, Fossil Group’s shares had closed up 41.5% at a two-and-a-half-year high of $3.75 following the news of the IPO of its Indian unit. According to a <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2025-10-15/fossil-india-is-said-to-weigh-ipo-that-could-raise-400-million">Bloomberg News report</a>, Fossil India was in talks to raise $300 million to $400 million by selling as much as a 25% stake.The report noted that the talks were ongoing and that the size of the IPO or the possible timing of the offering could change.&nbsp;In early 2025, as part of a plan to save costs, the company planned to shut down around 50 retail locations and shift certain international markets to a distributor model. The firm is home to several premium brands such as Fossil Watches and Michele.&nbsp;<a href="https://stocktwits.com/symbol/VERI">Shares of Fossil Group</a> have jumped 125% this year and gained nearly 213% in the last 12 months.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/alibaba-executive-reportedly-says-company-beginning-to-see-return-on-ai-investment-in-e-commerce/ch6pRcFR3nf">Alibaba Executive Reportedly Says Company Beginning To See Return On AI Investment In E-Commerce: Forecasts ‘Very Significant’ Positive Impact</a>

Sign of Fossil Group outside a store in Orlando, Florida.

FOSL Stock Plunges After Extending Exchange Offer For Its Senior Notes Due 2026

Separately, the company stated that it is not currently pursuing an initial public offering of its subsidiary in India, following recent media reports about the subsidiary going public.

Equity

Shares of Ovid Therapeutics Inc. (OVID) jumped 18% in the pre-market session on Friday after the company announced positive results from an early-stage trial of its OV329, as well as the pricing of a $175 million placement.OV329 is being developed for the potential treatment of rare and treatment-resistant forms of epilepsy and seizures. It is believed to work by reducing the activity of GABA-AT, an enzyme that degrades GABA, an important inhibitory neurotransmitter in the brain. An increase in levels of GABA in the brain can potentially suppress neuronal hyperexcitability, known to cause seizures, the company said.The early-stage <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://investors.ovidrx.com/news/news-details/2025/Ovid-announces-positive-topline-results-for-the-next-generation-GABA-aminotransferase-inhibitor-OV329-that-demonstrate-strong-inhibitory-activity-and-a-potential-best-in-category-safety-profile/default.aspx">study</a>, which enrolled 68 healthy volunteers, was aimed at evaluating the safety, tolerability, pharmacokinetic, and pharmacodynamic activity of OV329. The drug demonstrated statistically significant inhibition of GABA-AT, matching or exceeding the inhibition demonstrated by therapeutic doses of first-generation GABA-AT inhibitor Vigabatrin (VGB), the company said. The drug also demonstrated a favorable safety and tolerability profile, it added. &nbsp;The company is now looking forward to initiating a mid-stage study evaluating OV329 in adult patients with drug-resistant focal onset seizures. The study is expected to start in Q2 2026 and be completed in mid-2027.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/OVID">OVID stock</a> stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:576/60;" src="https://news.stocktwits-cdn.com/Screenshot_2025_10_03_at_8_04_20_AM_png_cfbcdadc7f.webp" alt="OVID's Sentiment Meter and Message Volume as of 8:04 a.m. ET on Oct. 03, 2025 | Source: Stocktwits" width="576" height="60"><figcaption>OVID's Sentiment Meter and Message Volume as of 8:04 a.m. ET on Oct. 03, 2025 | Source: Stocktwits</figcaption></figure>Separately, Ovid on Friday also <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://investors.ovidrx.com/news/news-details/2025/Ovid-Therapeutics-Announces-Pricing-of-Private-Placement-Totaling-up-to-175-Million-in-Gross-Proceeds/default.aspx">announced</a> the pricing of a private placement totaling up to $175 million in proceeds. The financing transaction included participation from new investors alongside existing ones, the company said.The company stated that it intends to utilize the net proceeds from the initial closing of the financing deal, in conjunction with its existing cash, cash equivalents, and marketable securities, to fund research and development, general corporate expenses, and working capital requirements. It added that it expects its cash to fund its operating plan into 2028.A Stocktwits user applauded the funding news as “huge.”<stembedurl>https://stocktwits.com/Skeetz99/message/630905995</stembedurl>OVID stock is up 76% this year and approximately 45% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/esperion-shares-rally-after-patent-litigation-settlement-for-cholestrol-drugs/chCujWhR3Qb">Esperion Shares Rally After Patent Litigation Settlement For Cholesterol Drugs</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Ovid Therapeutics Stock Rallied 18% Pre-Market – Here’s Why

The company is now looking forward to initiating a mid-stage study evaluating OV329 in adult patients with drug-resistant focal onset seizures.

Eastman Kodak Co. (KODK) experienced a 366% surge in Stocktwits retail chatter in the last 24 hours after the photographic film products maker announced on the X platform that it is making a major move to strengthen pharmaceutical manufacturing within the U.S.&nbsp;&nbsp;<figure class="image"><img style="aspect-ratio:587/183;" src="https://news.stocktwits-cdn.com/Screenshot_2025_07_24_082242_png_3c927c29c7.webp" alt="Screenshot 2025-07-24 082242.png" width="587" height="183"></figure>A Stocktwits user said it is the ‘Kodak Moment’ for the company.<stembedurl>https://stocktwits.com/ScottBrownMBA/message/622209783</stembedurl>Another user expressed optimism, linking the news to the U.S. Japan trade deal.<stembedurl>https://stocktwits.com/Zorrelak/message/622217804</stembedurl>However, retail sentiment around the stock remained in ‘bearish’ territory with ‘low’ message volume levels.<figure class="image"><img style="aspect-ratio:975/117;" src="https://news.stocktwits-cdn.com/Screenshot_2025_07_24_083017_png_ac1c90c79d.webp" alt="KODK’s Sentiment Meter and Message Volume as of 08.30 a.m. ET on July 24, 2025 | Source: Stocktwits" width="975" height="117"><figcaption>KODK’s Sentiment Meter and Message Volume as of 08.30 a.m. ET on July 24, 2025 | Source: Stocktwits</figcaption></figure><a href="https://stocktwits.com/symbol/KODK">Eastman Kodak stock</a> inched 0.5% higher in Thursday’s premarket.Kodak ventured into pharmaceuticals after the company was awarded a $765 million federal loan in 2020, aimed at producing pharmaceutical ingredients, as part of a broader effort during the pandemic to strengthen the nation’s medical supply chain.In May of this year, CEO Jim Continenza stated that the company is retrofitting a facility at Eastman Business Park and has committed $20 million to expand U.S. manufacturing, according to a&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://rbj.net/2025/05/09/kodak-invests-20m-in-rochester-pharma-manufacturing-expansion/?utm_source=chatgpt.com">report</a> from the&nbsp;Rochester Business Journal.&nbsp;In the first quarter (Q1), the company’s revenue declined 1% year-on-year (YoY) to $243 million.&nbsp;“The group’s new cGMP manufacturing facility, which we expect to be online later this year, will expand our current pharma business into manufacturing FDA-regulated diagnostic test reagents. Our investment in the new pharma facility is just one example of our commitment to investing in U.S.-based manufacturing,” said&nbsp;Continenza after the Q1 earnings.As it evolves into pharmaceuticals, Kodak continues to support its traditional film operations and printing systems, including high-speed inkjet technology.Eastman Kodak stock has gained over 8% year-to-date and over 25% in the last 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/alphabet-manhattan-associates-at-and-t-draw-heavy-retail-chatter-on-stocktwits/ch8yupaR5HI">Alphabet, Manhattan Associates, AT&amp;T Draw Heavy Retail Chatter On Stocktwits Among Tech Stocks: More Details Inside</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Eastman Kodak Company logo is seen displayed on a smartphone screen.

A Kodak ‘Moment’? Company’s Pharma Expansion Plans Ignite 366% Surge In Retail Chatter

Kodak ventured into pharmaceuticals after the company was awarded a $765 million federal loan in 2020, aimed at producing pharmaceutical ingredients, as part of a broader effort during the pandemic to strengthen the nation’s medical supply chain.

Diversified Energy (DEC) stock gained in pre-market trade on Monday after the company said it would buy Maverick Natural Resources from private equity firm EIG for $1.28 billion.The deal, expected to close in the first half of 2025, would increase the share of oil in Diversified Energy’s total energy production mix.The energy firm said the deal would help nearly double its revenue, and the combined company would have a total production of about 200,000 barrels of oil equivalent per day.The overwhelming majority of Maverick’s production comes from the Western Anadarko Basin, the Ark-La-Tex region of East Texas, and the largest U.S. shale oilfield Permian Basin.Over the past one and half years, the Permian has been a focal point of deal activity in the U.S. due to its robust infrastructure and relatively lower production costs.<a href="https://stocktwits.com/symbol/DEC">Diversified Energy</a> said EIG would own 20% of the combined company once the transaction closes.Rusty Hutson, the CEO of Diversified Energy, will continue to serve in his position after the deal is completed.“The acquired producing assets have demonstrated leading well performance and are a natural fit with our operating advantage and existing acreage,” Hutson said.The company said it is liable to pay $50 million in termination fees under certain circumstances.Retail sentiment on Stocktwits jumped to ‘extremely bullish’ (96/100) territory from ‘bearish’(36/100) a day ago, while retail chatter remained ‘extremely high’.<figure class="image"><img style="aspect-ratio:886/206;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/DEC_Jan_27_e4c793b801.JPG" alt="DEC’s Sentiment Meter and Message Volume as of 08:20 a.m. ET on Jan. 27, 2025 | Source: Stocktwits" width="886" height="206"><figcaption>DEC’s Sentiment Meter and Message Volume as of 08:20 a.m. ET on Jan. 27, 2025 | Source: Stocktwits</figcaption></figure>Earlier this month, Diversified Energy had agreed to buy some natural gas assets from Summit Natural Resources for $45 million.Over the past year, the stock has gained 32.5%.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/super-micro-stock-crashes-below-30-support-premarket/chbkvyQRov">Super Micro Stock Crashes Below $30 Support Premarket As DeepSeek Fears Rattle AI Stocks: Retail Sentiment Mixed</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

An oil pumpjack in a field on March 24, 2024 in Grandfalls, Texas. (Photo by Brandon Bell/Getty Images)

Diversified Energy Stock Rises After Deal To Buy Maverick Natural Resources for $1.28B: Retail’s Elated

The deal, expected to close in the first half of 2025, would increase the share of oil in Diversified Energy’s total energy production mix.

EA Series Trust - EA Bridgeway Omni Small-Cap Value ETF

Short-Term Volatility, Then Markets Move On

Sustained Risk-Off Until Fed Path Is Clear

Little Impact — Fundamentals Still Rule

Other – Comment Below

Markets pulled back after reports that the DOJ opened a criminal investigation into Federal Reserve Chair Jerome Powell, raising concerns about central bank independence. With rate cuts, inflation, and political pressure all in focus, how do you think this standoff will impact markets in 2026?

How Will the Powell Investigation Impact Markets in 2026?

Current Price	$24.57
Prev Close	$24.50
Open	$24.52
Dividend Yield	N/A
50-Day Moving Average	$23.33
Beta	N/A
Avg. Volume	183,162.95
PE Ratio	N/A

52-Week High	$24.71
52-Week Low	$16.55
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A
Enterprise Value/EBITDA	N/A

BSVO
EA Series Trust - EA Bridgeway Omni Small-Cap Value ETF

Feed

News

Sentiment

Fundamentals

Info

Latest BSVO News

BSVOEA Series Trust - EA Bridgeway Omni Small-Cap Value ETF